Integrated Wealth Concepts LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 3,139 shares of the life sciences company’s stock, valued at approximately $730,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. Acadian Asset Management LLC lifted its stake in shares of Illumina by 312.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock valued at $702,000 after purchasing an additional 1,525 shares during the period. Dimensional Fund Advisors LP increased its position in Illumina by 3.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock valued at $82,853,000 after buying an additional 7,114 shares in the last quarter. Dakota Wealth Management increased its position in Illumina by 13.8% in the 1st quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock valued at $288,000 after buying an additional 100 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in Illumina by 16.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after buying an additional 116 shares in the last quarter. Finally, Baird Financial Group Inc. increased its position in Illumina by 10.2% in the 1st quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after buying an additional 4,548 shares in the last quarter. 88.66% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Illumina news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $190.08, for a total value of $95,040.00. Following the completion of the sale, the senior vice president now directly owns 46,022 shares in the company, valued at $8,747,861.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Illumina Stock Down 1.5 %
Illumina stock opened at $189.29 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.22. The firm has a 50-day moving average of $194.33 and a 200-day moving average of $206.36. Illumina, Inc. has a 1-year low of $179.03 and a 1-year high of $248.87.
Illumina Company Profile
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
- Five stocks we like better than Illumina
- Basic Materials Stocks Investing
- JetBlue Airlines May Have Entered A Buy Zone, Check This First
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Investors Are Staying Bullish On Marriot International
- Best Restaurant Stocks to Invest in Now
- Do Caterpillar’s Results Hint at a Looming Infrastructure Bubble?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
